Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Done, gone tomorrow
MK
All the common shares will be canceled very soon according to today
8-K! TVINQ did last week. BOGAQ did yesterday. Now it is NFLDQ...
I'd say this play has a 1% chance of running, the problem is these guys dont have the money to do a further clinical trial, its stuck at .04 for eternity
<< Back
Northfield Laboratories Announces Decision to Wind Down Business
EVANSTON, Ill.--(BUSINESS WIRE)--May. 15, 2009-- Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that it has determined to wind down its business operations and carry out an orderly disposition of its assets.
Following its review and analysis of the complete response letter received from the Food and Drug Administration on April 30, 2009, Northfield determined that further clinical development of a reformulated version of its PolyHeme® human red cell substitute product, including additional clinical trials, would likely be required before it could again seek to obtain FDA approval. Northfield concluded that the time and substantial expense required to complete this additional clinical development, together with significant uncertainty that FDA approval would ultimately be obtained, made it unlikely that sufficient additional capital could be raised to support such further product development.
On May 8, 2009, Northfield announced that it had terminated substantially all operational and staff employees at its manufacturing facility and headquarters.
Northfield cautioned that in view of the Company’s obligations to creditors, expenses expected to be incurred in connection with the wind down process and uncertainty regarding the realizable value of the Company’s non-cash assets, no assurance can be given that any amounts will be available for distribution to shareholders in connection with the winding down of the Company’s business. Northfield has retained counsel to explore the options available to wind down its business.
Why the chart looks nice, I went over value investors post history he seems like hes full of chit I doubt he owns any of the plays.
just because you post on a board on a daily routine doesn't mean you own the stock. anyways im going to see if this bio has a chance or not
No Armani I'm not...I can only stand to be in one stock with Value Investor at a time....actually I'm thinking about dumping that one as well.
Hey cowboy, do you follow this anymore? any phase 3 drugs in the pipeline?
the chart looks steady, im going to whip out a can of DD on this
http://stockcharts.com/h-sc/ui?s=nfldq&p=D&b=5&g=0&id=p23463897154
Who are those very stupid sellers which sold over 100,000 shares at
$0.04 yesterday? $0.04 must be the forever unbreakable bottom!
This stock is finally bottomed out at $0.04! We should expect to sell our shares at $0.08 ~ $0.1 within a couple of days. $0.04 must
be the forever unbreakable support! Anyway many stupid sellers sold
the shares at $0.04 ~ $0.06 of which the majority was bought by me.
I am happy with my 3M damn cheap shares!
The following press release pretty much says it all...possible Chapter 7 if they do as proposed.
Northfield Laboratories Announces Decision to Wind Down Business
EVANSTON, Ill., May 15, 2009 (BUSINESS WIRE) -- Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that it has determined to wind down its business operations and carry out an orderly disposition of its assets.
Following its review and analysis of the complete response letter received from the Food and Drug Administration on April 30, 2009, Northfield determined that further clinical development of a reformulated version of its PolyHeme(R) human red cell substitute product, including additional clinical trials, would likely be required before it could again seek to obtain FDA approval. Northfield concluded that the time and substantial expense required to complete this additional clinical development, together with significant uncertainty that FDA approval would ultimately be obtained, made it unlikely that sufficient additional capital could be raised to support such further product development.
On May 8, 2009, Northfield announced that it had terminated substantially all operational and staff employees at its manufacturing facility and headquarters.
Northfield cautioned that in view of the Company's obligations to creditors, expenses expected to be incurred in connection with the wind down process and uncertainty regarding the realizable value of the Company's non-cash assets, no assurance can be given that any amounts will be available for distribution to shareholders in connection with the winding down of the Company's business. Northfield has retained counsel to explore the options available to wind down its business.
About Northfield Laboratories
Northfield Laboratories is developing a hemoglobin-based oxygen-carrying red blood cell substitute, PolyHeme. PolyHeme is a solution of chemically modified human hemoglobin that requires no cross-matching and is therefore compatible with all blood types. It has an extended shelf life in excess of 12 months. For further information, visit http://www.northfieldlabs.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are identified by the use of such terms as "intends," "expects," "plans," "estimates," "anticipates," "should," "believes" and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various risks and uncertainties, including those described from time to time in our periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. We do not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the time such statement is made. All subsequent written and oral forward-looking statements attributable to Northfield or any person acting on our behalf are qualified by this cautionary statement.
SOURCE: Northfield Laboratories Inc.
CONTACT:
Fleishman-Hillard Media Inquiries: Tom Laughran, 312-932-2834 tom.laughran@fleishman.com or Investor Inquiries: Northfield Laboratories, 847-864-3500
Copyright Business Wire 2009
Will the shareholders get anything since the business winding down?
As I predicted the new low $0.061 is unbreakable bottom even it is a CH11 with vary bad management team! We should see $0.122 soon...
Another new 52-week low $0.061 was created! What is going on? I am
holding my huge position firmly no matter how sick the MMs are!
With $0.4 per share book value why the company filed the CH11? Will
this stock be traded at its book value $0.4 or above in the future?
WE MADE IT TO THE PINK SHEETS....
Seems someone wants this to be traded...hmmmm....
in @ 0.113$
nice chart
http://finviz.com/chart.ashx?t=NFLD&ta=0&p=d&s=l
Buy Confirmed on www.americanbulls.com
Northfield Laboratories (NFLD) Chapter 11 Petition Filed...
6/2/2009;
Northfield Laboratories filed for Chapter 11 protection with the U.S. Bankruptcy Court in the District of Delaware, case number 09-11924. The Company is represented by Ian Connor Bifferato of Bifferato LLC. The filing was made to facilitate the Company's previously-announced plan to wind down its business operations and carry out an orderly disposition of its assets. The Company states that the decision to file was made "after an exhaustive review of alternative options and is seen as the most favorable means for the Company to continue its wind down process and liquidate its remaining assets for the benefit of its creditors and other parties in interest." The Company expects to file with the Court a liquidating plan and related disclosure statement.
Morning all, just stopped by to check this out....chart is a nice pincher set-up....wonder what all the volume is if they are closing up?
yeah news has been horrible lately but im playing the volume/rumor play if any. we shall see.
Northfield Laboratories to shut down business operations
Monday 05/18/2009 1:08 PM ET - Datamonitor
Related Companies
Symbol Last %Chg
NFLD 0.2067 158.37%
As of 1:40 PM ET 5/22/09
Northfield Laboratories, a developer of blood substitute product, has determined to wind down its business operations and carry out an orderly disposition of its assets.
Following its review and analysis of the complete response letter received from the FDA on April 30, 2009, Northfield determined that further clinical development of a reformulated version of its PolyHeme human red cell substitute product, including additional clinical trials, would likely be required before it could again seek to obtain FDA approval.
Northfield concluded that the time and substantial expense required to complete this additional clinical development, together with significant uncertainty that FDA approval would ultimately be obtained, made it unlikely that sufficient additional capital could be raised to support such further product development.
On May 8, 2009, Northfield announced that it had terminated substantially all operational and staff employees at its manufacturing facility and headquarters
the only news i can find is from yesterday and it's not really much http://www.chicagotribune.com/business/chi-thu-notebook-nfld-plantmay21,0,4891494.story
yeah ill probably be exiting after tuesdays morning gap before the plummet. unless news hits before that.
Nice catch:)
I'm not too sure what it could be at this point? They are closing plants & shutting there doors/winding down the business.
At these levels I wouldn't hesitate to take some profits at some point.JMHO
GLTA
grabbed a bunch @.13. something big happening here. not too sure but like my chances. somebody knows something.
Okayyyyyyyyy! Don't really understand why such a move up today with very little pullback so far?
This company is suppose to be done?
200% gain????? On what exactly???
Congrats to the early birds today:)
This will probably be it's last bounce people....Take advantage of it:) They will be closing there doors very soon. Winding down there business.
GLTA
I live in CHICAGO area,been following this in local papers and my account..
no doubt about it!
it's a beautiful thing
how low will it go? i bet if they can get there chit together and send another application to the FDA it might work
I hope NFLD gives an PR-update on the friday news/situation..
buy and hold till that moment..
Well, the FDA didn't approve their product, so we shall see.
I got in at .18, we'll see what's happening next monday (buyout?)
I was in the POS at 17.00,then their first
Polyheme/FDA bomb dropped after salt water
was found to be just as effective.
Probably not the best test,but that was
that.
Thankyou
This ones looking pretty interesting. It's a make it or break it kinda deal. I bought in on Monday so let's see where this goes. From the looks of it we won't have too long to wait. Anyone know what's been going on?
Potential revenues from Polyheme is Huge if approved. I am not concerned about that at all. I am concerned about the fact that FDA is still not ready to approve blood substitute products in the market due to safety concerns. Lets see
All,
I'm new on this board. I'm starting my DD on NFLD.
Does someone know where I can find reliable information regarding the potential revenues for PolyHeme?
Regards,
FTR
Good. Let's Not talk too much till the right time. We got some more time
Not the only one now bagfull.
I am looking forward to more posts here and more posters here very soon.
of this there is no doubt! off to a great start this year, made my entry into Northfield in early October 08, best of luck with this one!
UPDATE 1-Northfield's red blood cell drug granted fast review
Tue Dec 30, 2008 9:58am EST
Dec 30 (Reuters) - Northfield Laboratories Inc (NFLD.O) said U.S. regulators have granted a priority review for the company's experimental treatment for the loss of red blood cell, sending its shares to a new-year high.
Shares of the company more than doubled to $1.21 in morning trade on Nasdaq. They closed at 56 cents Monday on Nasdaq.
On Oct. 29, the company submitted a Biological License Agreement (BLA) for PolyHeme, its human hemoglobin-based red cell substitute.
Under the priority review, which is granted to products that are considered to be more advanced over existing therapies, the Food and Drug Administration takes shorter time, usually six months from the date of submission of the application, to make its decision.
The company expects for an FDA decision on the PolyHeme BLA by April 30, 2009. (Reporting by Anand Basu in Bangalore; Editing by Jarshad Kakkrakandy)
http://www.reuters.com/article/marketsNews/idINBNG38286120081230?rpc=44
My Comment: I know that this is old news, but it looks like a decision won't be made for another four months. Buying a 1000 shares Friday as a lottery ticket.
You have to love the action. Great play up and down.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
102
|
Created
|
03/12/06
|
Type
|
Free
|
Moderators |
Status: CH11 Process and Business-Winding-Down. No Operation At All.
How PolyHeme® Is Made
Northfield uses a proprietary process of separation, filtration, chemical modification, purification and formulation to produce PolyHeme®.
First, hemoglobin is extracted from red blood cells and filtered to remove impurities. This purified hemoglobin is then chemically modified and purified using a multi-step process to create a polymerized form of hemoglobin. The modified hemoglobin is then incorporated into an electrolyte solution.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |